Gregory J Grosicki1,2, Thomas G Travison3,4, Hao Zhu4, Jay Magaziner5, Ellen F Binder6, Marco Pahor7, Rosaly Correa-de-Araujo8, Peggy M Cawthon9,10, Shalender Bhasin11, Denise Orwig5, Susan Greenspan12, Todd Manini7, Joe Massaro13, Adam Santanasto14, Sheena Patel10, Roger A Fielding1. 1. Nutrition, Exercise Physiology and Sarcopenia Laboratory, Jean Mayer USDA Human Nutrition Research Center, Tufts University, Boston, Massachusetts. 2. Department of Health Sciences and Kinesiology, Biodynamics and Human Performance Center, Georgia Southern University (Armstrong Campus), Savannah, Georgia. 3. Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts. 4. Marcus Institute for Aging Research, Hebrew SeniorLife, Boston, Massachusetts. 5. School of Medicine, University of Maryland, Baltimore, Maryland. 6. Division of Geriatrics & Nutritional Science, Washington University School of Medicine, St. Louis, Missouri. 7. Department of Aging and Geriatric Research, University of Florida, Gainesville, Florida. 8. U.S. Department of Health and Human Services, Division of Geriatrics and Clinical Gerontology, National Institute of Aging, National Institutes of Health, Bethesda, Maryland. 9. San Francisco Coordinating Center, California Pacific Medical Research Institute, San Francisco, California. 10. Department of Epidemiology and Biostatistics, University of California, San Francisco, California. 11. Research Program in Men's Health: Aging and Metabolism, Boston Claude D. Pepper Older Americans Independence Center for Function Promoting Therapies, Brigham and Women's Hospital, Boston, Massachusetts. 12. Department of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania. 13. Department of Biostatistics, Harvard Clinical Research Institute, Boston, Massachusetts. 14. Department of Epidemiology, Center for Aging and Population Health, University of Pittsburgh, Pittsburgh, Pennsylvania.
Abstract
BACKGROUND: The Sarcopenia Definitions and Outcomes Consortium (SDOC) is a collaborative initiative seeking to develop and evaluate cut-points for low muscle strength and lean mass that predict an increased risk for slowness (usual walking speed <.8 m/s) among older adults. OBJECTIVES: The goal of the present study was to provide clinicians and researchers with an understanding of the diagnostic implications of using SDOC variables and cut-points in mobility-limited older adults. Using data from older individuals with specific conditions that render them at increased risk for mobility limitation, we evaluated the performance characteristics (ie, sensitivity and specificity) of five putative sarcopenia parameters and then compared these values with previously recommended diagnostic criteria for sarcopenia. DESIGN: Retrospective analysis of six randomized controlled trials enriched in persons at risk for mobility limitation. SETTING: National and international geriatric clinical research centers. PARTICIPANTS: A total of 925 mobility-limited older adults (≥55 years of age; 58% women) were included in the analysis. MEASUREMENTS: The prevalence of low muscle strength and lean mass were assessed using five candidate metrics discriminative of slowness. Analyses of sensitivity and specificity were used to compare muscle weakness criteria with published diagnostics for sarcopenia. RESULTS: Odds ratios (ORs) supported maximal grip strength (Grip max <35.5 and 20.0 in men and women, respectively) as the most discriminative of slowness in both men and women (OR = 3.66 and 3.53, respectively). More men (58%) than women (30%) fell below sex-specific maximal grip cut-points. When applying previously recommended sarcopenia component definitions in our population, we found that fewer individuals met those criteria (range = 6%-32%). CONCLUSION: A greater number of individuals fall below SDOC Grip max cut-points compared with previous recommendations. Clinicians and researchers working with older adults may consider these thresholds as an inclusive means to identify candidates for low-risk lifestyle promyogenic and function-promoting therapies. J Am Geriatr Soc 68:1445-1453, 2020.
BACKGROUND: The Sarcopenia Definitions and Outcomes Consortium (SDOC) is a collaborative initiative seeking to develop and evaluate cut-points for low muscle strength and lean mass that predict an increased risk for slowness (usual walking speed <.8 m/s) among older adults. OBJECTIVES: The goal of the present study was to provide clinicians and researchers with an understanding of the diagnostic implications of using SDOC variables and cut-points in mobility-limited older adults. Using data from older individuals with specific conditions that render them at increased risk for mobility limitation, we evaluated the performance characteristics (ie, sensitivity and specificity) of five putative sarcopenia parameters and then compared these values with previously recommended diagnostic criteria for sarcopenia. DESIGN: Retrospective analysis of six randomized controlled trials enriched in persons at risk for mobility limitation. SETTING: National and international geriatric clinical research centers. PARTICIPANTS: A total of 925 mobility-limited older adults (≥55 years of age; 58% women) were included in the analysis. MEASUREMENTS: The prevalence of low muscle strength and lean mass were assessed using five candidate metrics discriminative of slowness. Analyses of sensitivity and specificity were used to compare muscle weakness criteria with published diagnostics for sarcopenia. RESULTS: Odds ratios (ORs) supported maximal grip strength (Grip max <35.5 and 20.0 in men and women, respectively) as the most discriminative of slowness in both men and women (OR = 3.66 and 3.53, respectively). More men (58%) than women (30%) fell below sex-specific maximal grip cut-points. When applying previously recommended sarcopenia component definitions in our population, we found that fewer individuals met those criteria (range = 6%-32%). CONCLUSION: A greater number of individuals fall below SDOC Grip max cut-points compared with previous recommendations. Clinicians and researchers working with older adults may consider these thresholds as an inclusive means to identify candidates for low-risk lifestyle promyogenic and function-promoting therapies. J Am Geriatr Soc 68:1445-1453, 2020.
Authors: Shehzad Basaria; Andrea D Coviello; Thomas G Travison; Thomas W Storer; Wildon R Farwell; Alan M Jette; Richard Eder; Sharon Tennstedt; Jagadish Ulloor; Anqi Zhang; Karen Choong; Kishore M Lakshman; Norman A Mazer; Renee Miciek; Joanne Krasnoff; Ayan Elmi; Philip E Knapp; Brad Brooks; Erica Appleman; Sheetal Aggarwal; Geeta Bhasin; Leif Hede-Brierley; Ashmeet Bhatia; Lauren Collins; Nathan LeBrasseur; Louis D Fiore; Shalender Bhasin Journal: N Engl J Med Date: 2010-06-30 Impact factor: 91.245
Authors: Jonathan Afilalo; Mark J Eisenberg; Jean-François Morin; Howard Bergman; Johanne Monette; Nicolas Noiseux; Louis P Perrault; Karen P Alexander; Yves Langlois; Nandini Dendukuri; Patrick Chamoun; Georges Kasparian; Sophie Robichaud; S Michael Gharacholou; Jean-François Boivin Journal: J Am Coll Cardiol Date: 2010-11-09 Impact factor: 24.094
Authors: Stephanie Studenski; Subashan Perera; Kushang Patel; Caterina Rosano; Kimberly Faulkner; Marco Inzitari; Jennifer Brach; Julie Chandler; Peggy Cawthon; Elizabeth Barrett Connor; Michael Nevitt; Marjolein Visser; Stephen Kritchevsky; Stefania Badinelli; Tamara Harris; Anne B Newman; Jane Cauley; Luigi Ferrucci; Jack Guralnik Journal: JAMA Date: 2011-01-05 Impact factor: 56.272
Authors: W Jack Rejeski; Roger A Fielding; Steven N Blair; Jack M Guralnik; Thomas M Gill; Evan C Hadley; Abby C King; Stephen B Kritchevsky; Michael E Miller; Anne B Newman; Marco Pahor Journal: Contemp Clin Trials Date: 2005-04 Impact factor: 2.226
Authors: Sarinnapha Vasunilashorn; Antonia K Coppin; Kushang V Patel; Fulvio Lauretani; Luigi Ferrucci; Stefania Bandinelli; Jack M Guralnik Journal: J Gerontol A Biol Sci Med Sci Date: 2009-01-31 Impact factor: 6.053
Authors: Mary P Kotlarczyk; Subashan Perera; David A Nace; Neil M Resnick; Susan L Greenspan Journal: J Am Geriatr Soc Date: 2017-11-20 Impact factor: 5.562
Authors: Sheena M Patel; Kate A Duchowny; Douglas P Kiel; Rosaly Correa-de-Araujo; Roger A Fielding; Thomas Travison; Jay Magaziner; Todd Manini; Qian-Li Xue; Anne B Newman; Karol M Pencina; Adam J Santanasto; Shalender Bhasin; Peggy M Cawthon Journal: J Am Geriatr Soc Date: 2020-07-07 Impact factor: 5.562
Authors: Davis A Englund; Dylan R Kirn; Afsaneh Koochek; Hao Zhu; Thomas G Travison; Kieran F Reid; Åsa von Berens; Michael Melin; Tommy Cederholm; Thomas Gustafsson; Roger A Fielding Journal: J Gerontol A Biol Sci Med Sci Date: 2017-12-12 Impact factor: 6.053
Authors: Dawn E Alley; Michelle D Shardell; Katherine W Peters; Robert R McLean; Thuy-Tien L Dam; Anne M Kenny; Maren S Fragala; Tamara B Harris; Douglas P Kiel; Jack M Guralnik; Luigi Ferrucci; Stephen B Kritchevsky; Stephanie A Studenski; Maria T Vassileva; Peggy M Cawthon Journal: J Gerontol A Biol Sci Med Sci Date: 2014-05 Impact factor: 6.053
Authors: Peggy M Cawthon; Todd Manini; Sheena M Patel; Anne Newman; Thomas Travison; Douglas P Kiel; Adam J Santanasto; Kristine E Ensrud; Qian-Li Xue; Michelle Shardell; Kate Duchowny; Kristine M Erlandson; Karol M Pencina; Roger A Fielding; Jay Magaziner; Timothy Kwok; Magnus Karlsson; Claes Ohlsson; Dan Mellström; Vasant Hirani; Eva Ribom; Rosaly Correa-de-Araujo; Shalender Bhasin Journal: J Am Geriatr Soc Date: 2020-07-07 Impact factor: 5.562
Authors: Marian L Neuhouser; Rebecca P Hunt; Linda Van Horn; James M Shikany; Marcia L Stefanick; Karen C Johnson; Robert Brunner; Brad Cannell; Irene E Hatsu; Lesley F Tinker Journal: Prev Med Date: 2020-08-12 Impact factor: 4.018
Authors: Anna H Wu; V Wendy Setiawan; Unhee Lim; Chiu-Cheng Tseng; Kami K White; John Shepherd; Heinz Josef Lenz; Iona Cheng; Daniel O Stram; Christopher Haiman; Lynne R Wilkens; Loïc Le Marchand Journal: J Cachexia Sarcopenia Muscle Date: 2022-01-30 Impact factor: 12.910
Authors: Alex Barreto de Lima; Duarte Henrinques-Neto; Gustavo Dos Santos Ribeiro; Elvio Rúbio Gouveia; Fátima Baptista Journal: Int J Environ Res Public Health Date: 2022-07-29 Impact factor: 4.614